140 related articles for article (PubMed ID: 30603116)
1. Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer.
Mancini BR; Stein S; Lloyd S; Rutter CE; James E; Chang BW; Lacy J; Johung KL
J Gastrointest Oncol; 2018 Dec; 9(6):982-988. PubMed ID: 30603116
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
3. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation.
Koay EJ; Zaid M; Aliru M; Bagereka P; Van Wieren A; Rodriguez MJ; Jacobson G; Wolff RA; Overman M; Varadhachary G; Pant S; Wang H; Tzeng CW; Ikoma N; Kim M; Lee JE; Katz MH; Tamm E; Bhosale P; Taniguchi CM; Holliday EB; Smith GL; Ludmir EB; Minsky BD; Crane CH; Koong AC; Das P; Wang X; Javle M; Krishnan S
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(3):444-453. PubMed ID: 35863672
[TBL] [Abstract][Full Text] [Related]
4. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy.
Hill C; Sehgal S; Fu W; Hu C; Reddy A; Thompson E; Hacker-Prietz A; Le D; De Jesus-Acosta A; Lee V; Zheng L; Laheru DA; Burns W; Weiss M; Wolfgang C; He J; Herman JM; Meyer J; Narang A
Cancer Med; 2022 Apr; 11(7):1659-1668. PubMed ID: 35142085
[TBL] [Abstract][Full Text] [Related]
5. Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study.
Lewis S; Sastri SC; Arya S; Mehta S; Patil P; Shrivastava S; Phurailatpam R; Shrikhande SV; Engineer R
J Gastrointest Oncol; 2019 Jun; 10(3):474-482. PubMed ID: 31183197
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study.
Michalet M; Bordeau K; Cantaloube M; Valdenaire S; Debuire P; Simeon S; Portales F; Draghici R; Ychou M; Assenat E; Dupuy M; Gourgou S; Colombo PE; Carrere S; Souche FR; Aillères N; Fenoglietto P; Azria D; Riou O
Front Oncol; 2022; 12():842402. PubMed ID: 35356227
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study.
Bordeau K; Michalet M; Keskes A; Valdenaire S; Debuire P; Cantaloube M; Cabaillé M; Portales F; Draghici R; Ychou M; Assenat E; Mazard T; Samalin E; Gauthier L; Colombo PE; Carrere S; Souche FR; Aillères N; Fenoglietto P; Azria D; Riou O
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612004
[TBL] [Abstract][Full Text] [Related]
9. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma.
Yoo C; Hwang I; Song TJ; Lee SS; Jeong JH; Park DH; Seo DW; Lee SK; Kim MH; Byun JH; Park JH; Hwang DW; Song KB; Lee JH; Lee W; Chang HM; Kim KP; Kim SC; Ryoo BY
Ther Adv Med Oncol; 2020; 12():1758835920953294. PubMed ID: 32983266
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1).
Arcelli A; Buwenge M; Macchia G; Bertini F; Guido A; Deodato F; Cilla S; Scotti V; Rosetto ME; Djan I; Parisi S; Mattiucci GC; Cellini F; Fiore M; Bonomo P; Belgioia L; Niespolo RM; Gabriele P; Di Marco M; Simoni N; Mazzarotto R; Morganti AG;
Cancer Med; 2020 Nov; 9(21):7879-7887. PubMed ID: 32910549
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen.
Yoo C; Kang J; Kim KP; Lee JL; Ryoo BY; Chang HM; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Hwang DW; Song KB; Lee JH; Kim SC
Oncotarget; 2017 Jul; 8(28):46337-46347. PubMed ID: 28564637
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
[TBL] [Abstract][Full Text] [Related]
13. Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer.
Chadha AS; Skinner HD; Gunther JR; Munsell MF; Das P; Minsky BD; Delclos ME; Chatterjee D; Wang H; Clemons M; George G; Singh PK; Katz MH; Fleming JB; Javle MM; Wolff RA; Varadhachary GR; Crane CH; Krishnan S
PLoS One; 2016; 11(6):e0156910. PubMed ID: 27336466
[TBL] [Abstract][Full Text] [Related]
14. A comparison of three treatment strategies for locally advanced and borderline resectable pancreatic cancer.
Lloyd S; Chang BW
J Gastrointest Oncol; 2013 Jun; 4(2):123-30. PubMed ID: 23730507
[TBL] [Abstract][Full Text] [Related]
15. The impact of intensified staging and combined therapies in locally advanced pancreatic cancer: a secondary analysis of prospective studies.
Fiore M; Petrianni GM; Trecca P; D'Ercole G; Coppola A; La Vaccara V; Taralli S; Cimini P; Greco C; Ippolito E; Calcagni ML; Beomonte Zobel B; Caputo D; Coppola R; Ramella S; D'Angelillo RM
Int J Surg; 2023 Sep; ():. PubMed ID: 37737898
[TBL] [Abstract][Full Text] [Related]
16. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis.
Damm M; Efremov L; Birnbach B; Terrero G; Kleeff J; Mikolajczyk R; Rosendahl J; Michl P; Krug S
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503138
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis.
Yoo C; Shin SH; Kim KP; Jeong JH; Chang HM; Kang JH; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Hwang DW; Song KB; Lee JH; Ryoo BY; Kim SC
Cancers (Basel); 2019 Feb; 11(3):. PubMed ID: 30813624
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
[TBL] [Abstract][Full Text] [Related]
20. Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer.
Zakem SJ; Mueller AC; Meguid C; Torphy RJ; Holt DE; Schefter T; Messersmith WA; McCarter MD; Del Chiaro M; Schulick RD; Goodman KA
HPB (Oxford); 2021 Jul; 23(7):1072-1083. PubMed ID: 33277184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
